Prognostic Biomarkers in Samples From Young Patients With Acute Myeloid Leukemia

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Studying samples of blood or tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is studying prognostic biomarkers in cell samples from young patients with acute myeloid leukemia.

Detailed Description
-----------------
OBJECTIVES: Primary To determine the percentage of primary acute myeloid leukemia (AML) samples with increased Stat3 signaling pathway activity. To evaluate the presence of constitutive Stat3 activation and the sensitivity of Stat3 activation to low- and high-doses of cytokines. To evaluate the expression levels of Stat3 protein and the upstream and downstream regulators of Stat3 activation. Secondary To classify samples according to a Stat3 activation pattern and correlate this result with event-free survival (EFS) and overall survival (OS). OUTLINE: Cryopreserved AML specimens are analyzed for pStat3 and pStat5 levels, response to cytokine levels, and expression level of proteins known to influence stat activity by flow cytometry and western blot assays. Results are also compared with prognostic variables determined in CCG-291 study, including age, race, WBC, and cytogenetic risks.

Official Title
-----------------
Stat3 Activation as a Potential Prognostic Marker and Therapeutic Target in Pediatric AML-II

Conditions
-----------------
Leukemia

Intervention / Treatment
-----------------
* Genetic: protein expression analysis
* Genetic: western blotting
* Other: flow cytometry
* Other: laboratory biomarker analysis
* Other: medical chart review


Participation Criteria
=================
Eligibility Criteria
-----------------
DISEASE CHARACTERISTICS: Diagnosis of acute myeloid leukemia (AML) Cryopreserved AML specimens PATIENT CHARACTERISTICS: Not specified PRIOR CONCURRENT THERAPY: Not specified

Ages Eligible for Study
-----------------
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: protein expression analysis|nan|
|Genetic: western blotting|nan|
|Other: flow cytometry|nan|
|Other: laboratory biomarker analysis|nan|
|Other: medical chart review|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation of constitutive pStat3 with inducible pStat3 |  |  | 
| Correlation of pStat3 responses with pStat5 responses, and G-CSF-induced responses with IL-6- induced responses |  |  | 
| Correlation of pStat3- and pStat5-induced responses with surface G-CSFR and gp130 expression |  |  | 
| Correlation of constitutive pStat3/pStat5 with levels of the negative regulators SOCS3 and SHP1 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Correlation between pStat3/pStat5 and event-free survival and overall survival |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
childhood acute myeloid leukemia/other myeloid malignancies